{"preliminary_commentary":{"by_channel":{"x_thread":22,"youtube":6,"podcast":5,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04712643\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"TALENTACE","nct_id":"NCT04712643","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=talentace-nct04712643. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive atezolizumab plus bevacizumab on Day 1 of a 21-Day cycle, after every on-demand transarterial chemoembolization procedure.","label":"Arm A: atezolizumab + bevacizumab + TACE","type":"EXPERIMENTAL"},{"description":"Participants will receive on-demand transarterial chemoembolization.","label":"Arm B: TACE alone","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-02-01","type":"ESTIMATED"},"conditions":["Hepatocellular Carcinoma"],"enrollment":{"count":342,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq"],"type":"DRUG"},{"name":"Becavizumab","otherNames":["Avastin"],"type":"DRUG"},{"name":"Transarterial chemoembolization (TACE)","otherNames":[],"type":"DEVICE"}],"last_update":"2026-10-26","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-02-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"TACE Progression-Free Survival (TACE PFS) as Determined by Investigator","timeFrame":"Randomization to untreatable progression or TACE failure/refractoriness or death (up to approximately 46 months)"},{"measure":"Overall Survival (OS)","timeFrame":"Randomization to death from any cause (up to approximately 94 months)"}],"references":[{"citation":"Kudo M, Ogasawara S, Liu R, Gu S, Wang K, Zhao M, Hu H, Liu Z, Lin K, Liu J, Lin Z, Zhang Y, Peng T, Song J, Ueno M, Zhu J, Bai L, Tong L, Shi Y, Han G, Dong J. On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2026 Aug 25:S2468-1253(26)00212-8. doi: 10.1016/S2468-1253(26)00212-8. Online ahead of print.","pmid":"42641632","type":"DERIVED"}],"start_date":{"date":"2021-03-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","url":"https://clinicaltrials.gov/study/NCT04712643"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/talentace-nct04712643"}